Your Environment. Your Health.

Skip Navigation

Selected Publications

Molecular & Genetic Epidemiology Group

  1. Taioli E, Sears V, Watson A, Flores-Obando RE, Jackson MD, Ukoli FA, deSyllos Colus IM, Fernandex P, McFarlane-Anderson N, Ostrander EA, Rodrigues IS, Stanford JL, Taylor JA, Tulloch-Reid M, Ragin CCR. Polymorphisms in CYP17 and CYP3A4 and Prostate Cancer in Men of African Descent. The Prostate 2013 73(6):666-676. [Abstract ]
  2. Xu Z, Bensen JT, Smith GJ, Mohler JL, Taylor JA. GWAS SNP Replication among African American and European American men in the North Carolina-Louisiana prostate cancer project (PCaP). Prostate 2011 71(8):881-91.[Abstract ]
  3. Flake GP, Rivera MP, Funkhouser WK, Maygarden SJ, Meadows KL, Long EH, Stockton PS, Jones TC, Yim HW, Slebos RJC, Taylor JA. Detection of pre-invasive lung cancer: technical aspects of the LIFE project. Toxicologic pathology 2007 35(1):65-74.[Abstract ]
  4. Xu Z, Kaplan NL, Taylor JA. Tagster: Efficient selection of LD tag SNPs in single or multiple populations. Bioinformatics (Oxford, England) 2007 23(23):3254-3255.[Abstract ]
  5. Yim HW, Slebos RJC, Randell SH, Umbach DM, Parsons AM, Rivera MP, Detterbeck FC, Taylor JA. Smoking is associated with increased telomerase activity in short-term cultures of human bronchial epithelial cells. Cancer Letters 2007 246:24-33. [Abstract ]
  6. Flake GP, Rivera MP, Funkhouser WK, Slebos RJC, Maygarden SJ, Meadows KL, Long EH, Stockton PS, Jones TC, Taylor JA. Detection of pre-invasive lung cancer: Technical aspects of the LIFE Project. Toxicologic Pathology 2007 35:65-74
  7. Goodman M, Bostick RM, Ward KC, Terry PD, VanGils CH, Taylor JA, Mandel JS. Lycopene intake and prostate cancer risk: effect modification by plasma antioxidants and XRCC1 genotype. Cancer and Nutrition 2006 55(1):13-20.[Abstract ]
  8. Taylor JA, Xu ZL, Kaplan NL, Morris RW. How well do HapMap haplotypes identify common haplotypes of genes? A comparison with haplotypes of 334 genes resequenced in the Environmental Genome Project. Cancer Epidemiology Biomarkers and Prevention. 2006 15:133-7.[Abstract ]
  9. Terry PD, Umbach DM, Taylor JA. APE1 genotype and risk of bladder cancer: Evidence for effect modification by smoking. Int J Cancer 2006 31:516-8.[Abstract ]
  10. Stern MC, Conway K, Li Y, Mistry K, Taylor JA. DNA repair gene polymorphisms and probability of p53 mutation in bladder cancer. Molecular Carcinogenesis 2006 45:715-719.[Abstract ]
  11. Terry PD, Umbach DM, Taylor JA. No association between SOD2 or NQO1 genotypes and risk of bladder cancer. Cancer Epidemiology Biomarkers and Prevention 2005 14:753-4. [Abstract ]
  12. Slebos RJC, Livanos E, Yim H-W, Randell SH, Parsons AM, Detterbeck FC, Rivera MP, Taylor JA. Chromosomal abnormalities in bronchial epithelium from smokers, non-smokers and lung cancer patients. Cancer Genetics and Cytogenetics. 2005 159:137-42. [Abstract ]
  13. Kamel F, Umbach DM, Hu H, Munsat TL, Shefner JM, Taylor JA, Sandler DP. Lead exposure as a risk factor for amyotrophic lateral sclerosis. Neurodegener Dis 2005 2:195-201.[Abstract ]
  14. Dunson DB, Taylor JA. Approximate Bayesian Inference for Quantiles. J. Nonparametric Statistics 2005 17:385-400.
  15. Slebos RJC, Little RE, Umbach DM, Antipkin Y, Zadaorozhnaja TD, Mendel NA, Sommer CA, Conway K, Parrish E, Gulino S, Taylor JA Mini- and microsatellite mutations in children from Chernobyl accident cleanup works. Mut. Research, 2004, 559:143-51.[Abstract ]
  16. Terry PD, Kamel F, Umbach DM, Lehman TA, Hu H, Sandler DP, Taylor JA VEGF promoter haplotype and amyotrophic lateral sclerosis (ALS) J. Neurogenetics 2004 18:429-34. [Abstract ]
  17. Li L, Umbach DM, Terry P, Taylor JA Application of the GA/KNN method to SELDI proteomics data Bioinformatics, 2004, 20:1638-40.[Abstract ]
  18. Slebos RJC, Umbach DM, Sommer CA, Horner GA, Choi JY, Taylor JA Analytical and statistical methods to evaluate microsatellite allelic imbalance in small amounts of DNA. Lab. Invest., 2004, 84:648-57.[Abstract ]
  19. Schroeder JC, Conway K, Li Y, Mistry K, Bell DA, Taylor JA P53 mutations in bladder cancer: evidence for exogenous versus endogenous risk factors. Cancer Research, 2003, 63:7530-8.[Abstract ]
  20. Jugessur A, Lie RT, Wilcox AJ, Murray JC, Taylor JA, Saugstad OD, Vindenes HA, Abyholm FE Cleft Palate, Transforming Growth Factor Alpha Gene Variants, and Maternal Exposures: Assessing Gene-Environment Interactions in Case-Parent Triads. Genetic Epidemiology, 2003, 25:367-74.[Abstract ]
  21. Kamel F, Umbach DM, Lehman TA, Park LP, Munsat TL, Shefner JM, Sandler DP, Hu H, Taylor JA Amyotrophic Lateral Sclerosis, Lead, and Genetic Susceptibility: Polymorphisms in the gamma-Aminolevulinic Acid Dehydratase and Vitamin D Receptor Genes. Environmental Health Perspectives, 2003, 111:1335-9.[Abstract ]
  22. Jin YH, Clark AB, Slebos RJC, Al-Refai H, Taylor JA, Kunkel TA, Resnick MA, Gordenin DA Cadmium is a mutagen that acts by inhibiting mismatch repair. Nature Genetics, 2003, 34:329-9.[Abstract ]
  23. Dunson DB, Watson M, Taylor JA Bayesian latent variable models for median regression on multiple outcomes. Biometrics, 2003, 59:296-304.[Abstract ]
  24. Jugessur A, Wilcox AJ, Lie RT, Murray JC, Taylor JA, Ulvik A, Vindenes H, Abyholm F. Exploring the effects of methylenetetrahydrofolate reductase gene variants C677T and A1298C on the risk of orofacial clefts in 261 Norwegian case-parent triands. Am. J. Epidemiology, 2003, 157:1083-91.[Abstract ]
  25. Jugessur A, Lie RT, Wilcox AJ, Murray JC, Taylor JA, Saugstad OD, Vindenes H, Abyholm F. Variants of developmental genes (TGFalpha, TGFbeta3, and MSX1) and their associations with facial clefts A case-parent triad analysis. Genetic Epidemiology, 2003, 24:230-9.[Abstract ]
  26. Slebos JC, Oh DS, Umbach DM, Taylor JA. Mutations in tetranucleotide repeats following DNA damage depend on repeat sequence and carcinogenic agent. Cancer Research, 2002, 62:6052-60. [Abstract ]
  27. Stern MC, Umbach DM, Lunn RM, Taylor JA. DNA repair gene XRCC3 codon 241 polymorphism, its interaction with smoking and XRCC1 polymorphisms and bladder cancer risk. Cancer Epidemiology Biomarkers and Prevention, 2002, 11:939-943.[Abstract ]
  28. vanGils CH, Bostick RM, Stern MC, Taylor JA. Differences in base excision repair capacity may modulate the effect of dietary antioxidant intake on prostate cancer risk: an example of polymorphisms in the XRCC1 gene. Cancer Epidemiology Biomarkers and Prevention, 2002, 11:1279-84.[Abstract ]
  29. Engel LS, Taioli E, Pfeiffer R, Garcia-Closas1 M, Marcus P, Lan1 Q, Boffetta P, Vineis P, Autrup H, Bell DA, Branch RA, Brockmller J, Daly AK, Heckbert SR, Kalina1 I, Kang D, Katoh T, Lafuente A, Lin HJ, Romkes M, Taylor JA, Rothman1 N. Pooled Analysis and Meta-analysis of Glutathione S-Transferase M1 and Bladder Cancer: A Huge Review Am J Epidemiol, 2002, 156 No. 2,: 95-109. [Abstract ]
  30. van Gils CH, Conway K, Li Y, Taylor JA. HRAS1 variable number of tandem repeats polymorphism and risk of bladder cancer. Int J Cancer, 2002, 100: 414-418.[Abstract ]
  31. Thompson TE, Rogan PK, Risinger JI, Taylor JA. Splice variants, but not mutations, of DNA Polymerase b are common in bladder cancer. Cancer Research, 2002, 62:3251-3256.[Abstract ]
  32. Stern MC, Johnson LR, Bell DA, Taylor JA. XPD codon 751 polymorphism, metabolism genes, smoking, and bladder cancer risk. Cancer Epidemiology Biomarkers and Prevention., 2002, 11:1004-1011.[Abstract ]
  33. Hoppin JA, Tolbert PE, Taylor JA, Schroeder JC, Holly EA. Potential for selection bias with tumor tissue retrieval for molecular epidemiology studies. Ann Epidemiol, 2002, 12:1-6.[Abstract ]
  34. Devereux TR, Stern MC, Flake GP, Yu MC, London SJ, Taylor JA. CTNNB1 mutations and b-catenin protein accumulation in human hepatocellular carcinomas associated with high exposure to aflatoxin B1. Mol Carcinogenesis, 2001, 31:68-73.[Abstract ]
  35. Slebos RJC, Taylor, JA. A novel host cell reactivation assay to assess homologous recombination capacity in human cancer cell lines. Biochemical and Biophysical Research Communications, 2001, 281:212-219.[Abstract ]
  36. Stern, MC, Umbach DM, Yu MC, London SJ, Zhang Z-Q, Taylor JA. Hepatitis B, aflatoxin B1, and p53 codon 249 mutation hepatocellular carcinomas from Guangxi, People's Republic of China, and a meta-analysis of existing studies Cancer Epidemiology Biomarkers and Prevention, 2001, 10:617-625. [Abstract ]
  37. Stern MC, Umbach DM, van Gils CH, Lunn RM, Taylor JA. DNA repair gene XRCC1 polymorphisms, smoking, and bladder cancer risk. Cancer Epidemiology Biomarkers and Prevention, 2001, 10:125-131. [Abstract ]
  38. Slebos RJC, Hoppin JA, Tolbert PE, Holly EA, Brock J, Zhang RH, Bracci PM, Foley J, Stockton P, McGregor LM, Flake G, Taylor JA. K-ras and p53 in pancreatic cancer: Association with medical history, histopathology and environmental exposures in a population-based study. Cancer Epidemiology Biomarkers and Prevention, 2000, 9:1223-1232. [Abstract ]
  39. Blazer DG, Umbach DM, Bostick RM, Taylor JA. Vitamin D receptor polymorphisms and prostate cancer. Mol Carcinogenesis, 2000, 27: 18-23.[Abstract ]
  40. Lunn RM, Bell DA, Mohler JL, Taylor JA. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2). Carcinogenesis, 1999, 20: 1727-1731.[Abstract ]
  41. Burroughs KD, Dunn SE, Barrett JC, Taylor JA. Insulin-like Growth Factor-I: A key regulator of human cancer risk? J Natl Cancer Inst, 1999, 91: 579-581. [Abstract ]
  42. Wilcox AJ, Taylor JA, Sharp RR, London SJ. Genetic determinism and over-protection of human subjects. Nature Genetics, 1999, 21: 36. [Abstract ]
  43. Slebos RJC, Resnick MA, Taylor JA. Inactivation of the p53 tumor suppressor gene via a novel Alu rearrangement. Cancer Res, 1998, 58: 5333-5336.[Abstract ]
  44. Lancaster, JM, Berchuck, A, Carney, ME, Wiseman, R, Taylor JA. Progesterone receptor gene polymorphism and risk for breast and ovarian cancer. Br J Cancer, 1998, 78: 277. [Abstract ]
  45. Taylor JA, Umbach DM, Stephens E, Castranio T, Paulson D, Robertson C, Mohler J, Bell DA. The role of N-acetylation polymorphisms in smoking-associated bladder cancer, evidence of a gene-gene-environment 3-way interaction. Cancer Res, 1998, 58: 3603-3610.[Abstract ]
  46. London SJ, Lehman TA, Taylor JA. Myeloperoxidase genetic polymorphism and lung cancer risk. Cancer Res, 1997, 57: 5001-5003.[Abstract ]
  47. Bell DA, Taylor JA. Genetic analysis of complex diseases. Science [Technical Comments], 1997, 275: 1327-1328. [Abstract ]
  48. Taylor JA, Hirvonen A, Watson, M, Pittman G, Mohler JL, Bell DA. Association of prostate cancer with vitamin D receptor gene polymorphism. Cancer Res, 1996, 56: 4108-4110.[Abstract ]
  49. Chen H, Sandler DP, Taylor JA, Watson M, Shore DL, Liu E, Bell DA. Increased risk for myelodysplastic syndromes in individuals with glutathione transferase theta 1 (GSTT1) gene defect. Lancet, 1996, 347: 295-297.[Abstract ]
  50. Taylor JA, Li Y, Mason T, Mettlin C, Vogler WJ, Maygarden S, Liu E. p53 mutations in bladder tumors from arylamine-exposed workers Cancer Res, 1996, 55: 294-298. [Abstract ]
  51. Hirvonen A, Taylor JA, Wilcox AJ, Berkowitz G, Schachter B, Chaparro C, Bell DA. Xenobiotic metabolism genes and the risk of recurrent spontaneous abortion. Epidemiology, 1996, 7: 206-208.[Abstract ]
  52. Packenham JP, Taylor JA, Anna CH, White CM, Devereux TR. Homozygous deletions but no sequence mutations in coding regions of p15 or p16 in human primary bladder tumors. Mol Carcinogenesis, 1995, 14: 147-151. [Abstract ]
  53. McDonald JW, Taylor JA, Watson MA, Saccomanno G, Devereux TR. p53 and K-ras in radon-associated lung adenocarcinoma. Cancer Epi Biomarkers Prev, 1995, 4: 791-793.[Abstract ]
  54. Lancaster JM, Brownlee HA, Wiseman RW, Taylor JA. P53 polymorphism in ovarian and bladder cancer. Lancet (letter), 1995, 346: 182.[Abstract ]
  55. Packenham JP, Taylor JA, White CW, Anna CH, Barrett JC, Devereux TR. Homozygous deletions at chromosome 9p21 and mutation analysis of p16 and p15 in microdissected primary non small cell lung cancers. Clinical Cancer Res, 1995, 1: 687-690.[Abstract ]
  56. Taylor JA, Watson MA, Devereux TR, Michels R, Saccomanno G, Anderson M. p53 mutation hotspot in radon-associated lung cancer. Lancet, 1994, 343: 86-87.[Abstract ]

Back to Top